Pfizer adjusts after CFO exit and trial setback, shares steady in S&P 500 trade
28.06.2026 - 13:34:31 | ad-hoc-news.de
By Christina Vogel, Background & Management desk. Reviewed prior to publication on 2026-06-28, 13:34.
Pfizer Inc. (US7170811035) faces a demanding phase in NYSE trading as the group digests a recent chief financial officer departure and a setback in lung cancer research in the wake of its Seagen acquisition, while remaining a heavyweight in the S&P 500.
What recent commentary highlights
Motley Fool notes that Pfizer shares have lost more than 50 percent in value since late 2021, reflecting weak post-Covid financial results despite efforts to rebuild through acquisitions such as the roughly 43 billion dollar Seagen deal completed in 2023. The analysis points out that Pfizer’s oncology ambitions depend heavily on making this acquisition pay off.
In mid-June, Intellectia.ai reported on a Pfizer CFO exit that added pressure to the shares, with Wolfe Research analyst Alexandria Hammond keeping an Underperform rating while lifting the price target from 25 to 26 dollars, underlining cautious sentiment toward the stock. The firm described the latest earnings print as “rather uneventful”, signaling muted enthusiasm despite incremental guidance detail.
Clinical miss and oncology focus
According to Motley Fool, Pfizer recently disclosed that the antibody-drug conjugate sigvotatug vedotin failed to meet a key overall survival endpoint in a phase 3 trial in previously treated non-small cell lung cancer, a disappointment for its expanded oncology pipeline. This outcome raises questions about how quickly Pfizer can convert the Seagen platform into significant revenue growth.
The same report argues that despite this miss, Pfizer still has a broad late-stage pipeline and the capacity to absorb individual trial setbacks thanks to the scale of its research budget, though patience from shareholders has been tested by multi-year underperformance. Oncology remains central to management’s roadmap as Covid-era revenues fade and legacy products mature.
Further news and data on the Pfizer shares
More updates, historical performance figures and background reports on Pfizer are available in the dedicated topic section and on the group’s Investor Relations pages.
The business model and key products
Pfizer generates revenue primarily from patented prescription medicines across oncology, vaccines, immunology, cardiology and rare diseases, with blockbuster brands including Eliquis for stroke prevention and the Prevnar pneumococcal vaccine franchise. The company gained substantial cash flows from Covid-19 products such as the Comirnaty vaccine, co-developed with BioNTech, and the antiviral Paxlovid, though sales of these products have eased markedly as the pandemic phase has passed.
Where the stock trades currently
Pfizer shares (US7170811035) most actively trade on the NYSE under the ticker PFE, with MarketBeat citing a closing price of 24.28 dollars on June 26, 2026. The shares remain part of the large-cap S&P 500 index, anchoring the group among major global healthcare constituents.
Pfizer at a glance
- Company: Pfizer Inc.
- ISIN: US7170811035
- WKN: 852009
- Ticker: PFE
- Trading venue: NYSE
- Price (as of 2026-06-26, 15:59): 24.28 USD
- Market cap: 136.00 billion USD (as of 2026-06-26)
- Sector / industry: Pharmaceuticals
- Index membership: S&P 500, S&P 100
- Next earnings date: 2026-07-30
Disclaimer: This article provides factual information on Pfizer shares and the company’s business. It does not contain investment advice, personal recommendations or solicitations to buy or sell securities. Investors should conduct their own research or consult a licensed advisor before making investment decisions.
